Cantargia AB (CANTA) - Total Liabilities

Latest as of September 2025: Skr61.31 Million SEK ≈ $6.60 Million USD

Based on the latest financial reports, Cantargia AB (CANTA) has total liabilities worth Skr61.31 Million SEK (≈ $6.60 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Cantargia AB (CANTA) cash flow conversion to assess how effectively this company generates cash.

Cantargia AB - Total Liabilities Trend (2011–2024)

This chart illustrates how Cantargia AB's total liabilities have evolved over time, based on quarterly financial data. Check Cantargia AB liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Cantargia AB Competitors by Total Liabilities

The table below lists competitors of Cantargia AB ranked by their total liabilities.

Company Country Total Liabilities
Fulin Plastic Industry Cayman Holding Co Ltd
TW:1341
Taiwan NT$948.05 Million
Cibus Global LLC
NASDAQ:CBUS
USA $283.22 Million
Icares Medicus Inc
TWO:6612
Taiwan NT$1.25 Billion
Frontier Lithium Inc
V:FL
Canada CA$35.93 Million
Argent
JSE:ART
South Africa ZAC899.39 Million
Emerging Display Technologies Corp
TW:3038
Taiwan NT$1.30 Billion
Kura Sushi Asia Co Ltd
TWO:2754
Taiwan NT$3.41 Billion
EA Technique M Bhd
KLSE:5259
Malaysia RM147.39 Million

Liability Composition Analysis (2011–2024)

This chart breaks down Cantargia AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cantargia AB (CANTA) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.82 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.21 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.17 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cantargia AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cantargia AB (2011–2024)

The table below shows the annual total liabilities of Cantargia AB from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 Skr54.12 Million
≈ $5.82 Million
-1.54%
2023-12-31 Skr54.97 Million
≈ $5.92 Million
-35.42%
2022-12-31 Skr85.11 Million
≈ $9.16 Million
+26.10%
2021-12-31 Skr67.50 Million
≈ $7.26 Million
+101.02%
2020-12-31 Skr33.58 Million
≈ $3.61 Million
+41.18%
2019-12-31 Skr23.78 Million
≈ $2.56 Million
+45.04%
2018-12-31 Skr16.40 Million
≈ $1.76 Million
-42.12%
2017-12-31 Skr28.33 Million
≈ $3.05 Million
+172.85%
2016-12-31 Skr10.38 Million
≈ $1.12 Million
+212.02%
2015-12-31 Skr3.33 Million
≈ $358.15K
-79.24%
2014-12-31 Skr16.03 Million
≈ $1.73 Million
+1768.34%
2013-12-31 Skr858.07K
≈ $92.34K
+23.05%
2012-12-31 Skr697.32K
≈ $75.04K
-19.04%
2011-12-31 Skr861.27K
≈ $92.69K
--

About Cantargia AB

ST:CANTA Sweden Biotechnology
Market Cap
$101.72 Million
Skr945.22 Million SEK
Market Cap Rank
#19120 Global
#339 in Sweden
Share Price
Skr3.80
Change (1 day)
+1.06%
52-Week Range
Skr1.03 - Skr6.20
All Time High
Skr58.00
About

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more